Physician profile
Roya Sedghi
NPI 1871517037
$3,110.58
in general payments reported to CMS, 2019-2025
23 companies · $383 in 2025
The $383 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $401 · 2020: $315 · 2021: $782 · 2022: $643 · 2023: $327 · 2024: $259 · 2025: $383.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $969.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $968.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $553.62 | 2019-2022 | |
| Esperion Therapeutics, INC. | $507.97 | 2020-2025 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $422.53 | 2019-2023 | Jardiance |
| Novo Nordisk INC | $391.54 | 2019-2025 | Wegovy, Ozempic, Tresiba |
| Lilly USA, LLC | $159.28 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $145.15 | 2019-2025 | |
| Antares Pharma, INC. | $125.00 | 2022 | |
| Amgen INC. | $121.36 | 2023-2025 | Evenity, Prolia |
| Biocryst US Sales Co., LLC | $111.38 | 2023 | Orladeyo |
| Astellas Pharma US INC | $87.08 | 2019 | |
| Glaxosmithkline, LLC. | $86.87 | 2020-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Abbvie INC. | $77.42 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $66.68 | 2022-2025 | Airsupra, Fasenra |
| Harmony Biosciences LLC | $45.42 | 2025 | |
| Amarin Pharma, INC. | $44.00 | 2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beta Bionics, INC. | $31.85 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Grifols USA, LLC | $27.86 | 2025 | Prolastin-C Liquid |
| Mannkind Corporation | $23.78 | 2025 | |
| Abbott Laboratories | $21.50 | 2025 | Freestyle Libre 3 |
| Kowa Pharmaceuticals America, INC. | $16.93 | 2019 | |
| Novartis Pharmaceuticals Corporation | $16.47 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.26 | 2019 | |
| Ambu INC. | $10.63 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roya Sedghi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.